The White House has threatened to slap tariffs on apparel and footwear, leading retailers to speak out about how this would hurt business.Retailread more
"We are now embarking on a new Long March, and we must start all over again!" Xi Jinping said.Marketsread more
CNBC's Jim Cramer says Morgan Stanley cutting its worst-case forecast on Tesla so drastically from $97 per share appears to be a gimmick.Investingread more
U.S. aviation officials believe a bird strike may have led to the deadly crash of an Ethiopian Airlines Boeing 737 Max in March, according to a person familiar with the...Aerospace & Defenseread more
Craig Irwin of Roth Capital Partners said Apple tried to buy Tesla six years ago for a higher price than where the stock now trades.Technologyread more
The escalating trade war between China and the U.S. could increase pressure on the overall economy, according to Boston Fed President Eric Rosengren.The Fedread more
May outlined her new Brexit proposals which are being voted on by politicians next month.Europe Marketsread more
The Time's Up Legal Defense Fund, the American Civil Liberties Union and fast-food workers coalition Fight for $15 said Tuesday that they have filed 23 new complaints against...Restaurantsread more
Sales of existing U.S. homes fell 0.4% in April compared with March to a seasonally adjusted annualized rate of 5.19 million units, according to the National Association of...Real Estateread more
Japanese automakers say they generated more than 1.6 million jobs in the U.S. at manufacturing plants, dealerships and suppliers. Of those jobs, more than 94,000 people are...Autosread more
Morgan Stanley analysts said the reduction was driven by concerns around Chinese demand for Tesla products.Autosread more
In theory, Amgen's drug could help prevent migraines by inhibiting the receptors for calcitonin gene-related peptide. High levels of the molecule CGRP have been thought to be correlated with migraines.
Prior to the trial, the patients experienced 18 migraine days on average. Those that took the drug saw that number reduced by about 6.6 days, whereas patients who took the placebo only saw a reduction of 4.2 days. Amgen noted that the results are statistically significant for both groups.
"Amgen and Novartis look forward to discussing these results with global regulators. We believe that together with the Phase 3 episodic data that we expect in H2, the data could potentially support both chronic and episodic indications being granted, at least by some of the global regulators," said Kristen Davis, spokeswoman for Amgen.
The results are not surprising "given the consistency in treatment effect we've seen from all the CGRP inhibitors in development," according to a Wednesday analyst note from JPMorgan published before the announcement.
"We continue to view AMG 334 as one of the more important growth drivers for Amgen over the near-to-intermediate term and recognize the commercial potential that chronic and episodic migraine present," the firm said, adding that there's intense competition.
In April, an analyst at Citi estimated that the drug could be a $1.5 billion opportunity for Amgen. The firm also said that the drug could provide an upside of $8 per share.
— CNBC's Meg Tirrell contributed to this report.